World News: 14:00 GMT Wednesday 15th May 2019. [Illumina, Inc. via Businesswire via SPi World News]
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed another patent infringement suit against one of BGI Group’s subsidiaries, BGI Europe A/S. Illumina filed suit in the Maritime & Commercial High Court of Denmark.
“As we have previously stated, Illumina will continue to vigorously protect our patented technology and file patent suits where appropriate when our patents are infringed,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina.
The complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 3 002 289 B1. This patent covers Illumina’s proprietary sequencing-by-synthesis chemistry. The complaint also alleges that BGI’s use of the MGISEQ mark infringes Illumina’s registered EU Trademark No. 8972127 for the MISEQ name.
Earlier this year, Illumina filed a patent infringement suit against BGI Group’s subsidiary, Latvia MGI Tech SIA, in the Düsseldorf Regional Court in Germany. That complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 1 530 578 B1.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Business Wire: 14:00 GMT Wednesday 15th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.